2023
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
Kingston P, Blauvelt A, Strober B, Armstrong A. Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 156-165. PMID: 38188537, PMCID: PMC10768812, DOI: 10.1177/24755303231201336.Peer-Reviewed Original ResearchSevere plaque psoriasisTreatment of psoriasisPlaque psoriasisMechanism of actionLong-term extension studyNovel oral medicationsOral PDE4 inhibitorPalms/solesAcceptable safety profileHigh-risk patientsTreatment of adultsWeeks of treatmentTreatment of ModeratePivotal clinical studiesType I interferonPASI 75Tuberculosis evaluationSevere psoriasisIL-23Oral medicationsIL-12Blood testsSafety profilePsoriasis pathogenesisTriglyceride levelsDeucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
Lebwohl M, Egeberg A, Linaberry M, Hoyt K, Banerjee S, Kisa R, Strober B. Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program. SKIN The Journal Of Cutaneous Medicine 2023, 7: s116. DOI: 10.25251/skin.7.supp.116.Peer-Reviewed Original ResearchSevere plaque psoriasisAlanine aminotransferasePlaque psoriasisConcomitant medicationsWeeks 0Week 16Multiple laboratory parametersCommon Terminology CriteriaMean levelsTreatment of adultsWeeks of treatmentPatient-level dataOral placeboTerminology CriteriaAST elevationLiver transaminasesAminotransferase levelsCTCAE gradeLiver dysfunctionSystemic therapyLaboratory parametersAST levelsTreatment armsLiver conditionsSeverity gradeSafety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Thaçi D, Vender R, de Rie M, Conrad C, Pariser D, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball A. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal Of Dermatology 2023, 188: 22-31. PMID: 36689515, DOI: 10.1093/bjd/ljac021.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsOpen-label extensionSevere plaque psoriasisWeek 104Week 24PASI 100PASI 90Plaque psoriasisWeek 16Safety dataCommon treatment-emergent adverse eventsSerious treatment-emergent adverse eventsUpper respiratory tract infectionInitial randomization groupUnexpected safety findingsNew safety signalsRespiratory tract infectionsWeeks of treatmentLong-term resultsBaseline PASIBimekizumab groupBRIGHT trialMaintenance dosingPsoriasis AreaSafety findings
2022
POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
Fleischmann R, Thaçi D, Gooderham M, Strober B, Korman N, Banerjee S, Lehman T, Nowak M, Sreih A, Morita A, Mease P. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS. Annals Of The Rheumatic Diseases 2022, 81: 835.2-836. DOI: 10.1136/annrheumdis-2022-eular.1862.Peer-Reviewed Original ResearchConcomitant conventional synthetic DMARDsPhase 2 trialGrant/research supportKyowa Hakko KirinBristol-Myers SquibbCommon Terminology CriteriaPhase 3 trialSanofi GenzymeWeeks of treatmentLaboratory parametersPsoriatic arthritisLEO PharmaBoehringer IngelheimSun Pharmaceutical IndustriesUCB PharmaSpeaker feesNippon KayakuPlacebo nPsA trialsPsoriasis RegistryTerminology CriteriaWk 1Eli LillyLarge phase 3 trialsMitsubishi Tanabe
2017
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Papp K, Bachelez H, Blauvelt A, Winthrop K, Romiti R, Ohtsuki M, Acharya N, Braun D, Mallbris L, Zhao F, Xu W, Walls C, Strober B. Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis. British Journal Of Dermatology 2017, 177: 1537-1551. PMID: 28600810, DOI: 10.1111/bjd.15723.Peer-Reviewed Original ResearchConceptsIncidence rateTreatment groupsInfection rateSpecific infection rateSevere psoriasisSerious infectionsExposure-adjusted incidence ratesIRs of infectionsMonoclonal antibodiesWeeks of treatmentOverall infection rateIncidence of infectionOesophageal candidiasisBiological therapyPsoriasis trialsAntifungal therapyClinical trialsIxekizumabCandida infectionsPatientsLong-term exposureInfectionPsoriasisIncidenceTrials
2016
Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski B, Gottlieb A, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. Journal Of Psoriasis And Psoriatic Arthritis 2016, 1: 167-174. DOI: 10.1177/247553031600100406.Peer-Reviewed Original ResearchPsoriasis-related itchingSevere plaque psoriasisPhase 3 studyComplete symptom reliefWeeks of treatmentProportion of respondersGreater symptom improvementSymptom respondersPlaque psoriasisPsoriasis symptomsSymptom reliefComplete reliefSustained efficacySymptom improvementPsoriasis treatmentResults SubjectsSecukinumabEtanerceptItchingPainClear skinPlaceboMonoclonal antibodiesTreatment effectsPatientsSecukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. International Journal Of Dermatology 2016, 55: 401-407. PMID: 26866518, DOI: 10.1111/ijd.13236.Peer-Reviewed Original ResearchConceptsWeek 12Multicenter phase 3 studyPlacebo-controlled clinical trialInterleukin-17A antagonistPsoriasis-related itchingPlacebo treatment groupsSevere plaque psoriasisPhase 3 studyWeeks of treatmentProportion of subjectsPlaque psoriasisSevere psoriasisPsoriasis symptomsSystemic therapySymptom diaryClinical trialsSecukinumabTreatment responsePlaceboItchingPainTreatment groupsPhase 3PsoriasisAdults
2007
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel E, Strober B, Crowley J, Fivenson D, Woolley J, Yu E, Xia H, Chiou C, Stevens S. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007, 79: 322-6. PMID: 17500381.Peer-Reviewed Original Research
2006
Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
Gottlieb A, Kircik L, Eisen D, Jackson J, Boh E, Strober B, Frankel E, Xia H, Stevens S. Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Journal Of Dermatological Treatment 2006, 17: 343-352. PMID: 17853307, DOI: 10.1080/09546630600967166.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisDermatology clinicBody surface area involvementGlobal assessmentTolerability of etanerceptPatient global assessmentPhysician global assessmentSerious adverse eventsUse of etanerceptSurface area involvementActive psoriatic arthritisWeeks of treatmentBody surface areaEtanercept treatmentExperience diagnosingEtanercept therapyPlaque psoriasisAdverse eventsJoint painArea involvementJoint diseaseDisease scorePatientsArthritisPsoriasis